DDInter1804 DDInter856
Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke. The FDA label includes a black-box warning of neutropenia, aplastic anemia, thrombotic thrombocytopenia purpura, and agranulocytosis, so it is necessary to monitor patients' WBC and platelets when they are taking ticlopidine.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Ticlopidine {u} (Compound) binds {v} (Gene) MPO
Ticlopidine {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Ticlopidine {u} (Compound) downregulates {v} (Gene) RPS4Y1
Ticlopidine {u} (Compound) causes {v} (Side Effect) Flatulence
Ticlopidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Ticlopidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alteplase
Ticlopidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stiripentol
Ticlopidine {u} may lead to a major life threatening interaction when taken with {v} Drotrecogin alfa
Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Ticlopidine (Compound) binds MPO (Gene)
Ticlopidine (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Ticlopidine (Compound) downregulates RPS4Y1 (Gene)
Ticlopidine (Compound) causes Flatulence (Side Effect)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Alteplase
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Ticlopidine may lead to a major life threatening interaction when taken with Drotrecogin alfa